Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.
AM1 and AM2
RAMP1-3
adrenomedullin
angiogenesis
cancer
metastasis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
07
2020
accepted:
02
11
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
The development, maintenance and metastasis of solid tumors are highly dependent on the formation of blood and lymphatic vessels from pre-existing ones through a series of processes that are respectively known as angiogenesis and lymphangiogenesis. Both are mediated by specific growth-stimulating molecules, such as the vascular endothelial growth factor (VEGF) and adrenomedullin (AM), secreted by diverse cell types which involve not only the cancerogenic ones, but also those constituting the tumor stroma (i.e., macrophages, pericytes, fibroblasts, and endothelial cells). In this sense, anti-angiogenic therapy represents a clinically-validated strategy in oncology. Current therapeutic approaches are mainly based on VEGF-targeting agents, which, unfortunately, are usually limited by toxicity and/or tumor-acquired resistance. AM is a ubiquitous peptide hormone mainly secreted in the endothelium with an important involvement in blood vessel development and cardiovascular homeostasis. In this review, we will introduce the state-of-the-art in terms of AM physiology, while putting a special focus on its pro-tumorigenic role, and discuss its potential as a therapeutic target in oncology. A large amount of research has evidenced AM overexpression in a vast majority of solid tumors and a correlation between AM levels and disease stage, progression and/or vascular density has been observed. The analysis presented here indicates that the involvement of AM in the pathogenesis of cancer arises from: 1) direct promotion of cell proliferation and survival; 2) increased vascularization and the subsequent supply of nutrients and oxygen to the tumor; 3) and/or alteration of the cell phenotype into a more aggressive one. Furthermore, we have performed a deep scrutiny of the pathophysiological prominence of each of the AM receptors (AM
Identifiants
pubmed: 33489885
doi: 10.3389/fonc.2020.589218
pmc: PMC7815935
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
589218Informations de copyright
Copyright © 2021 Vázquez, Riveiro, Berenguer-Daizé, O’Kane, Gormley, Touzelet, Rezai, Bekradda and Ouafik.
Déclaration de conflit d'intérêts
Authors AO’K, JG, and OT are employed by the company Fusion Antibodies. RV, MR, and MB are stockholders of Early Drug Development Group. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Clin Endocrinol Diabetes. 1997;105(3):156-62
pubmed: 9228512
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24093-24099
pubmed: 31712427
J Pharmacol Exp Ther. 2009 Nov;331(2):513-21
pubmed: 19644039
Int J Mol Med. 2001 Dec;8(6):675-9
pubmed: 11712085
Endocrinology. 1997 Dec;138(12):5597-604
pubmed: 9389548
Genome Biol. 2001;2(12):REVIEWS3013
pubmed: 11790261
ChemMedChem. 2018 Sep 6;13(17):1797-1805
pubmed: 29979487
Trends Pharmacol Sci. 2001 Apr;22(4):201-7
pubmed: 11282421
Ann Neurol. 1990 Aug;28(2):183-7
pubmed: 1699472
Biochem Biophys Res Commun. 1995 Dec 26;217(3):832-8
pubmed: 8554605
Immunology. 2012 Jun;136(2):252-64
pubmed: 22348691
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
FEMS Immunol Med Microbiol. 1999 Apr;23(4):289-93
pubmed: 10225288
ChemMedChem. 2008 Sep;3(9):1345-55
pubmed: 18759242
Nat Commun. 2013;4:1672
pubmed: 23575676
Endocr Relat Cancer. 2010 Dec 13;18(1):C1-14
pubmed: 21051558
Peptides. 2008 Nov;29(11):2001-12
pubmed: 18708104
Oncotarget. 2016 Aug 23;7(34):55043-55056
pubmed: 27391260
Cancer Lett. 2008 Nov 28;271(2):314-22
pubmed: 18657357
J Transl Med. 2014 Dec 05;12:339
pubmed: 25475159
Peptides. 1997;18(1):133-6
pubmed: 9114462
Mol Cell. 2015 Jun 18;58(6):1040-52
pubmed: 25982113
Mol Med Rep. 2014 Sep;10(3):1295-302
pubmed: 24927229
Oncotarget. 2016 Sep 27;7(39):63374-63387
pubmed: 27556517
Biochem Biophys Res Commun. 1993 Apr 30;192(2):553-60
pubmed: 8387282
Biochem Biophys Res Commun. 1989 Jul 31;162(2):876-81
pubmed: 2787991
Eur J Neurosci. 2001 Aug;14(4):618-28
pubmed: 11556887
Am J Physiol. 1995 Apr;268(4 Pt 2):F657-63
pubmed: 7733322
Br J Cancer. 2007 Jun 18;96(12):1788-95
pubmed: 17519900
Gen Physiol Biophys. 2005 Dec;24(4):397-409
pubmed: 16474185
J Biol Chem. 2007 Jun 22;282(25):18094-9
pubmed: 17470425
Annu Rev Physiol. 1999;61:363-89
pubmed: 10099693
Mol Endocrinol. 2011 Jul;25(7):1244-53
pubmed: 21566080
Cancer Metastasis Rev. 2015 Dec;34(4):635-41
pubmed: 26328524
Mol Endocrinol. 2000 Jun;14(6):848-62
pubmed: 10847587
Curr Med Chem. 2007;14(15):1689-99
pubmed: 17584073
Anticancer Res. 2011 Feb;31(2):507-14
pubmed: 21378331
Br J Pharmacol. 1998 Nov;125(5):1081-7
pubmed: 9846648
J Biol Chem. 1996 Sep 20;271(38):23345-51
pubmed: 8798536
Int J Urol. 2002 Jun;9(6):285-95
pubmed: 12110091
Nature. 1998 May 28;393(6683):333-9
pubmed: 9620797
Int J Cancer. 2007 Jul 1;121(1):21-32
pubmed: 17290391
J Clin Invest. 1994 Nov;94(5):2158-61
pubmed: 7962564
Peptides. 1998;19(6):1043-7
pubmed: 9700753
Am J Pathol. 2002 Apr;160(4):1279-92
pubmed: 11943713
Am J Physiol Renal Physiol. 2001 Jun;280(6):F964-71
pubmed: 11352835
J Thorac Oncol. 2016 Jan;11(1):94-107
pubmed: 26762744
Br J Pharmacol. 2003 Oct;140(3):477-86
pubmed: 12970090
J Biol Chem. 2000 Oct 6;275(40):31438-43
pubmed: 10903324
Am J Physiol. 1998 Sep;275(3):E531-6
pubmed: 9725822
Biochem Biophys Res Commun. 2013 May 17;434(4):722-7
pubmed: 23583388
Clin Cancer Res. 2011 Dec 1;17(23):7230-9
pubmed: 21994414
N Engl J Med. 2017 Nov 30;377(22):2123-2132
pubmed: 29171821
J Biol Chem. 1999 Jun 4;274(23):16349-54
pubmed: 10347193
Cancer Res. 2001 Feb 1;61(3):1196-206
pubmed: 11221851
Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12581-6
pubmed: 18723674
Peptides. 2005 Dec;26(12):2610-5
pubmed: 15978699
J Natl Cancer Inst. 2002 Aug 21;94(16):1226-37
pubmed: 12189226
Nature. 1982 Jul 15;298(5871):240-4
pubmed: 6283379
Biochem Biophys Res Commun. 1998 Mar 27;244(3):832-7
pubmed: 9535752
Circ Res. 2004 Aug 20;95(4):415-23
pubmed: 15242974
N Engl J Med. 2004 Mar 11;350(11):1104-10
pubmed: 15014183
Protein Sci. 2013 Dec;22(12):1775-85
pubmed: 24115156
Oncol Rep. 2015 Aug;34(2):787-94
pubmed: 26035796
Carcinogenesis. 2000 Apr;21(4):793-7
pubmed: 10753217
FASEB J. 2003 Oct;17(13):1937-9
pubmed: 12897063
Biochem Biophys Res Commun. 2003 Nov 28;311(4):1072-7
pubmed: 14623291
J Clin Oncol. 2001 Feb 15;19(4):1207-25
pubmed: 11181687
Mol Cell Biol. 2006 Apr;26(7):2511-8
pubmed: 16537897
Endocrinology. 2004 Aug;145(8):3858-65
pubmed: 15107357
Mol Hum Reprod. 2000 Oct;6(10):867-72
pubmed: 11006313
Mol Pharmacol. 2008 Apr;73(4):1235-43
pubmed: 18174292
Headache. 2020 Apr;60(4):686-700
pubmed: 32073660
Breast Cancer Res. 2014 Dec 02;16(6):458
pubmed: 25439669
Hypertension. 2016 Sep;68(3):667-77
pubmed: 27402918
Peptides. 2001 Nov;22(11):1773-81
pubmed: 11754963
J Hum Hypertens. 2006 Aug;20(8):566-70
pubmed: 16625237
Endocr Rev. 1994 Apr;15(2):163-201
pubmed: 8026387
Metabolism. 2000 Jun;49(6):760-3
pubmed: 10877203
Biochem Biophys Res Commun. 2002 Jun 7;294(2):340-6
pubmed: 12051717
Trends Biochem Sci. 2006 Nov;31(11):631-8
pubmed: 17010614
Apoptosis. 2002 Dec;7(6):527-36
pubmed: 12370495
Int J Oncol. 2004 Dec;25(6):1781-7
pubmed: 15547717
Oncogene. 2008 Jan 17;27(4):506-18
pubmed: 17637748
J Pharmacol Exp Ther. 2016 Jan;356(1):223-31
pubmed: 26559125
Oncogene. 1998 Jan 22;16(3):409-15
pubmed: 9467966
J Biol Chem. 1995 Oct 27;270(43):25344-7
pubmed: 7592696
Int J Cancer. 2014 May 1;134(9):2041-50
pubmed: 24519534
J Neurochem. 1997 Feb;68(2):726-31
pubmed: 9003063
Br J Cancer. 2003 Nov 17;89(10):1927-33
pubmed: 14612905
Endocrinology. 2012 Apr;153(4):1850-60
pubmed: 22315449
J Histochem Cytochem. 1996 Jan;44(1):3-12
pubmed: 8543779
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):615-9
pubmed: 11149956
Handb Exp Pharmacol. 2019;255:121-130
pubmed: 30725283
Peptides. 2007 Nov;28(11):2164-70
pubmed: 17889965
Peptides. 2018 Dec;110:10-18
pubmed: 30385288
Endocrinology. 1986 Jan;118(1):46-51
pubmed: 3484451
J Biol Chem. 2005 Mar 11;280(10):9297-307
pubmed: 15613468
J Exp Clin Cancer Res. 2012 Mar 09;31:19
pubmed: 22400488
Oncotarget. 2017 Feb 28;8(9):15744-15762
pubmed: 28178651
Int J Gynecol Cancer. 2015 Jul;25(6):953-60
pubmed: 26098087
Biochim Biophys Acta Biomembr. 2018 Sep;1860(9):1765-1782
pubmed: 29518374
Biochem Biophys Res Commun. 2000 Apr 29;271(1):197-202
pubmed: 10777702
Biochem Biophys Res Commun. 2018 Feb 26;497(1):32-38
pubmed: 29408502
Nature. 1983 Jul 14-20;304(5922):129-35
pubmed: 6346105
Regul Pept. 2011 Jun 7;168(1-3):21-6
pubmed: 21362442
Br J Pharmacol. 2018 Jan;175(1):3-17
pubmed: 29059473
J Cardiovasc Pharmacol. 2010 Oct;56(4):413-9
pubmed: 20930593
Regul Pept. 2005 Apr 15;127(1-3):239-44
pubmed: 15680493
J Mol Cell Cardiol. 2005 Jan;38(1):145-51
pubmed: 15623431
Annu Rev Pharmacol Toxicol. 2016;56:469-87
pubmed: 26514202
Cancer Med. 2013 Apr;2(2):196-207
pubmed: 23634287
Endocrinology. 1994 Dec;135(6):2454-8
pubmed: 7988431
Cancer Res. 2012 Apr 15;72(8):1909-14
pubmed: 22508695
Oncogene. 2020 Feb;39(9):1914-1930
pubmed: 31754214
Microsc Res Tech. 2002 Apr 15;57(2):76-90
pubmed: 11921358
Oncogene. 2001 May 24;20(23):2937-45
pubmed: 11420706
N Engl J Med. 2017 Nov 30;377(22):2113-2122
pubmed: 29171818
Microbiol Immunol. 2009 Oct;53(10):573-81
pubmed: 19780971
Hypertens Res. 2003 Feb;26 Suppl:S61-70
pubmed: 12630813
J Clin Invest. 2008 Jan;118(1):29-39
pubmed: 18097473
J Pharmacol Exp Ther. 2010 Apr;333(1):152-60
pubmed: 20065019
Mol Metab. 2018 Feb;8:203-210
pubmed: 29203236
Cancer Res. 2012 Nov 15;72(22):5790-800
pubmed: 22993405
Biochem Biophys Res Commun. 1986 Oct 15;140(1):230-6
pubmed: 3778444
Circ Res. 2001 Jul 6;89(1):63-70
pubmed: 11440979
J Pharmacol Exp Ther. 2008 Feb;324(2):416-21
pubmed: 18039958
J Biol Chem. 2004 Feb 20;279(8):7264-74
pubmed: 14615490
J Mol Cell Cardiol. 2012 Jan;52(1):165-74
pubmed: 22100352
FASEB J. 2009 Oct;23(10):3424-35
pubmed: 19546305
Int J Cancer. 2009 Nov 15;125(10):2307-15
pubmed: 19610056
Am J Pathol. 2006 Jan;168(1):280-91
pubmed: 16400030
Biochem Biophys Res Commun. 1998 Mar 17;244(2):551-5
pubmed: 9514956
Mol Pharmacol. 2018 Apr;93(4):355-367
pubmed: 29363552
Endocrinology. 2006 Apr;147(4):1642-53
pubmed: 16384868
Physiol Rev. 2019 Jan 1;99(1):781-805
pubmed: 30540227
Endocr Relat Cancer. 2010 Jun 25;17(3):637-51
pubmed: 20483910
J Mol Endocrinol. 2006 Feb;36(1):81-9
pubmed: 16461929
Oncogene. 2002 Apr 25;21(18):2815-21
pubmed: 11973640
Int J Mol Sci. 2018 Oct 07;19(10):
pubmed: 30301274
J Biol Chem. 2015 Sep 18;290(38):23009-22
pubmed: 26198634
Braz J Med Biol Res. 2012 Mar;45(3):250-5
pubmed: 22370705
Hum Genet. 1985;70(3):259-63
pubmed: 2991116
Microsc Res Tech. 2002 Apr 1;57(1):28-39
pubmed: 11921354
Endocr Connect. 2015 Mar;4(1):43-9
pubmed: 25573159
Peptides. 2001 Nov;22(11):1713-8
pubmed: 11754956
Am J Ophthalmol. 2000 Apr;129(4):555-6
pubmed: 10764880
J Invest Dermatol. 2013 Jul;133(7):1768-76
pubmed: 23364478
Oncol Lett. 2015 Sep;10(3):1227-1232
pubmed: 26622655
Cell Metab. 2015 Dec 1;22(6):1059-67
pubmed: 26655697
Clin Cancer Res. 2013 Nov 15;19(22):6138-50
pubmed: 24100627
Intensive Care Med Exp. 2019 May 15;7(1):25
pubmed: 31093784
J Mol Cell Cardiol. 2014 Dec;77:73-85
pubmed: 25264174
Gen Comp Endocrinol. 2015 Feb 1;212:156-62
pubmed: 24815888
Hypertens Res. 2003 Feb;26 Suppl:S33-40
pubmed: 12630809
Gastroenterology. 2012 Dec;143(6):1510-1517.e1
pubmed: 22960655
Histol Histopathol. 2013 Jan;28(1):115-25
pubmed: 23233064
Mediators Inflamm. 2012;2012:717851
pubmed: 22685374
Oncogene. 2003 Feb 27;22(8):1238-42
pubmed: 12606950
Cardiovasc Res. 2008 Dec 1;80(3):339-45
pubmed: 18708640
Mol Pharmacol. 2008 Oct;74(4):1059-71
pubmed: 18593822
Cancer Res. 2007 Mar 15;67(6):2666-75
pubmed: 17363587
Prog Mol Biol Transl Sci. 2010;91:53-79
pubmed: 20691959
Am J Physiol. 1998 Apr;274(4):R979-84
pubmed: 9575959
Biochem Biophys Res Commun. 1993 Jul 30;194(2):720-5
pubmed: 7688224
Cold Spring Harb Perspect Med. 2012 Oct 01;2(10):
pubmed: 23028128
Endocrinology. 1998 May;139(5):2552-63
pubmed: 9564871
Braz J Med Biol Res. 2004 Aug;37(8):1247-53
pubmed: 15273827
Regul Pept. 2004 Apr 15;118(1-2):99-104
pubmed: 14759562
Biochem Biophys Res Commun. 2005 Feb 18;327(3):713-9
pubmed: 15649405
Diabetologia. 1991 Jan;34(1):52-4
pubmed: 2055340
Cardiovasc Res. 2016 Sep;111(4):398-409
pubmed: 27307317
Mol Endocrinol. 1999 Aug;13(8):1353-63
pubmed: 10446908
Ann N Y Acad Sci. 2001 Dec;947:26-33; discussion 33-4
pubmed: 11795275
Int J Mol Med. 2010 Aug;26(2):289-94
pubmed: 20596610
FASEB J. 2011 Jan;25(1):55-65
pubmed: 20802105
Clin Cancer Res. 2000 Jul;6(7):2808-14
pubmed: 10914728
Life Sci. 1994;55(5):PL85-90
pubmed: 8035644
FEBS Lett. 2004 Jan 2;556(1-3):53-8
pubmed: 14706825
Med Oncol. 2013 Mar;30(1):347
pubmed: 23269582
Diabetes. 1999 Feb;48(2):241-53
pubmed: 10334297
Sci Rep. 2017 Jan 16;7:40524
pubmed: 28091613
Int J Mol Med. 2005 Sep;16(3):431-5
pubmed: 16077951
J Clin Invest. 2008 Jan;118(1):40-50
pubmed: 18097475
Peptides. 2001 Nov;22(11):1693-711
pubmed: 11754955
Circ Res. 2006 Feb 3;98(2):262-70
pubmed: 16373602
Regul Pept. 2003 Apr 15;112(1-3):121-30
pubmed: 12667633
Oncotarget. 2015 Apr 10;6(10):7536-53
pubmed: 25924235
Circulation. 2013 Feb 19;127(7):842-53
pubmed: 23355623
Nat Rev Drug Discov. 2018 Jun 28;17(7):457-459
pubmed: 29950713
FEBS Lett. 1996 Jan 2;378(1):83-7
pubmed: 8549809
Circ Res. 2002 Oct 4;91(7):618-25
pubmed: 12364390
Dev Biol. 1999 May 15;209(2):254-67
pubmed: 10328919
J Leukoc Biol. 2006 Aug;80(2):237-44
pubmed: 16769769
Headache. 2017 May;57 Suppl 2:89-96
pubmed: 28485843
Int J Cancer. 2004 Mar 1;108(6):797-804
pubmed: 14712479
Eur J Heart Fail. 2019 Feb;21(2):163-171
pubmed: 30592365
Circulation. 2002 Jan 1;105(1):106-11
pubmed: 11772884
J Biol Chem. 2016 May 27;291(22):11657-75
pubmed: 27013657
Neurogastroenterol Motil. 2015 Jul;27(7):1038-49
pubmed: 25929169
Clin Sci (Lond). 2006 Jul;111(1):61-70
pubmed: 16515534
Inflamm Bowel Dis. 2013 Feb;19(2):E26-7
pubmed: 22294498
Regul Pept. 2006 Jan 15;133(1-3):115-22
pubmed: 16297990
Peptides. 2017 Feb;88:1-7
pubmed: 27940069
Curr Protein Pept Sci. 2013 Aug;14(5):407-15
pubmed: 23745704
Am J Physiol Regul Integr Comp Physiol. 2002 Jun;282(6):R1739-45
pubmed: 12010756
Biomed Pharmacother. 2019 Feb;110:775-785
pubmed: 30554116
Mol Cell Endocrinol. 2000 Apr 25;162(1-2):35-43
pubmed: 10854696
Regul Pept. 2009 Nov 27;158(1-3):127-31
pubmed: 19706311
Adv Exp Med Biol. 2012;744:49-60
pubmed: 22434107